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Abstract. Amongst the main reasons people at risk for Huntington’s disease (HD) have for undergoing predictive genetic
testing are planning a family and prevention of passing on an expanded CAG-repeat to future offspring. After having received
an unfavourable test result, a couple may consider prenatal testing in the foetus or preimplantation genetic diagnostic testing
(PGD) in embryos. Testing of the foetus or embryos is possible by means of direct testing of the expanded repeat. Optimal
reliability in testing the foetus or embryos requires the establishment of the origin of the repeats of both parents in the foetus.
For PGD the analysis is combined with or sometimes solely based on identification of the at-risk haplotype in the embryo.
This policy implies that in the context of direct testing, the healthy partner’s CAG repeat lengths in the HD gene are also
tested, but with the expectation that the repeat lengths of the partner are within the normal range, with the proviso that
the partner’s pedigree is free of clinically confirmed HD. However, recent studies have shown that the expanded repeat has
been observed more often in the general population than previously estimated. Moreover, we have unexpectedly observed
an expanded repeat in the non-HD partner in four cases which had far-reaching consequences. Hence, we propose that in the
context of reproductive genetic counselling, prior to a planned pregnancy, and irrespective of the outcome of the predictive
test in the HD-partner, the non-HD partner should also be given the option of being tested on the expanded allele. International
recommendations for predictive testing for HD should be adjusted.
Keywords: Huntington’s disease, preconceptional, prenatal genetic testing, preimplantation genetic diagnosis, CAG repeat,
intermediate alleles, partner testing
INTRODUCTION
Huntington’s disease (HD) is a hereditary
late onset neurodegenerative disease marked by
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2300 RC Leiden, The Netherlands. Tel.: +31 71 526 8033; Fax:
+31 71 526 6794; E-mail: a.tibben@lumc.nl.
involuntary movements, cognitive deterioration, and
behavioural disturbances with onset for the majority
of patients between 30 and 50 years of age [1]. So far,
symptomatic treatment is available that might reduce
the signs of HD and improve the well-being of the
patient. No treatment is yet available that affects its
etiology [2, 3]. HD is caused by a pathogenic muta-
tion of the HTT gene involving CAG trinucleotide
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repeats that exceed 35 [1, 4]. Identification of this
mutation enabled individuals at risk to find relief from
anxiety and uncertainty. Since, predictive genetic
testing is offered following internationally endorsed
recommendations [5].
Planning a family and prevention of passing on
an expanded CAG-repeat to future offspring are
amongst the main reasons for individuals at risk for
Huntington’s disease (HD) to apply for predictive
testing [6]. Identification of the expanded allele in
one of the partners enables a couple to consider pre-
natal testing (PD) when pregnant, or preimplantation
genetic diagnosis (PGD) before an existing preg-
nancy. Recent studies have shown that the frequency
of expanded repeats (ranging from intermediate to
full penetrance alleles) in the general population is
higher than expected [7]. Indeed, in our out-patient
HD predictive and prenatal testing clinic we have
observed expanded repeats in partners without an HD
family history. Consequently, we argue that irrespec-
tive of the test outcome of an individual at risk for
HD, the partner should also be offered testing if fam-
ily planning is a major and compelling reason to have
a predictive test. This test should preferably be done
before the couple is actually stepping into PD or PGD.
In this paper we describe four cases in which the
couples and clinicians involved were confronted with
an unexpected outcome of prenatal testing. In all
cases expanded repeats were observed in (or stem-
ming from) the presumed non-HD side of the couple.
THE CAG TRINUCLEOTIDE REPEAT
Four categories of repeat size ranges in the HTT
gene have been identified [8]. First, 40 CAG repeats or
more are full penetrance alleles (FPAs) and will cause
symptoms. Larger repeat sizes are associated with an
earlier age at onset [9, 10]. Second, 36 to 39 repeats
are incomplete or reduced penetrance alleles (RPAs)
and may cause symptoms, usually later in adult life.
Third, 27 to 35 repeats represent the category of inter-
mediate alleles (IA), which are not associated with
symptomatic disease, but sporadically show instabil-
ity and have the potential to expand into the RPA or
FPA range within one or more generations, mainly
through the paternal line [8, 11]. Fourth, repeats of
26 or less are not associated with HD and are stably
transmitted to the offspring.
Reports about the extent of the instability of IAs
and RPAs show differences in HD-populations. In
the Venezuelan HD kindreds, out of 69 transmitted
alleles in the IA range, only one expansion from 33
to 35 CAGs was found, but none expanded into the
RPA or FPA range while 14% of transmitted RPAs
expanded into the full penetrance range [12]. In a Por-
tuguese study, instability in FPAs was found in 66%
of all transmissions [13, 14]. Semaka et al. (2010)
examined the intergenerational stability of IAs. Over-
all 30% of the alleles were unstable upon transmission
with more expansions than contractions. The mean
change in the CAG size was 1.39 but the expansion
range was from +1 to +23 repeats. Expansions were
present in 24% of the transmissions from the 31 to
35 CAG range and in 14% of the transmissions from
the 27 to 30 CAG range [15, 16].
The repeat has been found especially unstable
when paternally transmitted [17]. Moreover, the
larger the expansion of the CAG repeat, the higher
the risk for further expansion [2, 17, 18]. However, it
has been demonstrated by analysing the CAG repeat
size in single spermatozoa that IAs can expand to
RPAs and FPAs [16, 19].
THE CAG TRINUCLEOTIDE REPEAT IN
THE GENERAL POPULATION
IAs in the HTT gene have been observed in 1–7%
of the general population, which can be considered
as relatively commonly present [11, 14, 16, 20].
In British Columbia, confirmed (0.7%) or probable
(7.1%) new mutations were found in HD patients
with a negative family history [21]. Kay et al. (2016)
reported that 1 in 400 individuals from the general
population has a repeat >35 (=0.246%), of which
0.041% has a repeat >39. General population RPA
penetrance rates are lower than penetrance rates
extrapolated from clinical cohorts [7]. In a Dutch
study on 1,690 patients tested to confirm or exclude
HD, 46,9% had a repeat size less than 27. Sixty
patients (3.6%) had an IA of whom half had no family
history concerning HD [22].
PRENATAL DIAGNOSIS AND
PREIMPLANTATION GENETIC
DIAGNOSIS
To prevent passing on the CAG expansion to their
offspring, individuals carrying an expanded CAG
repeat have the option of prenatal diagnosis (PD) or
PGD.
PD involves DNA testing of chorionic villi,
obtained by transcervical or transabdominal biopsy
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in the 10–13th week of pregnancy or of amniotic fluid
cells, obtained by amniocentesis from the 15th week
of pregnancy on.
PGD is performed on cleavage stage embryos on
the third day after fertilisation with ICSI or on blasto-
cyst cells after trophectoderm biopsy on day 5/6. For
HD, embryos with two normal alleles and/or normal
haplotypes are transferred to the uterus [23, 24]. Usu-
ally linkage methods such as STR marker analysis or
karyomapping will be added to or will replace anal-
ysis of the expanded and normal alleles to optimize
accuracy.
Direct testing of the expanded repeat and/or test-
ing with markers closely linked to the HD locus
enables testing of the fetal/embryonic material [25,
26]. Maternal samples are required in case of prena-
tal diagnosis to exclude maternal cell contamination.
Identification of the origin of the repeats or haplo-
types of both parents in the fetus or embryo is needed
to secure optimal reliability in PD as well as in PGD.
This policy implies that in the context of direct test-
ing, the healthy partner’s CAG repeat lengths in the
HD gene are also tested.
PD and PGD for HD are not as frequently chosen
as one would think based on the number of at-risk
individuals [27, 28], but for a substantial number of
couples morally compelling because they don’t want
to pass the risk on to their future children. Some cou-
ples might decide to only have children if they receive
favourable test results themselves. They intend to
refrain from having children in case of unfavourable
results and consider it as unacceptable confronting
their children with a parent who becomes affected by
HD in the future. Others with FPAs opt for prenatal
testing with the consequence to have the pregnancy
terminated in case of unfavourable results, or for
PGD.
CLINICAL OBSERVATIONS
We present four cases in which expanded CAG
repeats were unexpectedly observed in partners with-
out a known HD family history at the time of
counselling and genetic testing (see Fig. 1 and
Table 1).
Case 1
Twenty years ago, a married man at 50% risk and
33 years of age, requested testing for reasons of plan-
ning a family. He didn’t wish to pass the expanded
allele on to the next generation and didn’t want to
confront children with a father suffering from HD.
HD was not known in his wife’s family. The couple
intended not to have children if he should be identi-
fied as carrier of the expanded allele. He received a
favourable test result (21/23) and two children were
born. Four years ago, his wife died from a brain
tumour. Recently a relative informed him about infor-
mation received at another genetic centre that HD had
been diagnosed in his wife’s family and that his wife’s
father and grandfather were identified as having an
RPA. He wished to have his wife’s DNA analysed
to inform his adolescent children. His wife proved to
have an RPA (39). His daughters are consequently at
50% risk of having an expanded allele (most likely
an RPA, but as further expansion cannot be excluded,
possibly also an FPA).
Case 2
A man (31 years) at 50% risk applied for pre-
dictive testing. He was found to have 29/17 CAG
repeats which was still a great shock. He interpreted
the result as less bad than an FPA, but he and his wife
still felt they should as much as reasonably possible
avoid exposing their future offspring to the risk of
repeat expansion and related decisional issues. When
his wife became pregnant, they therefore insisted on
prenatal testing. After extensive counselling the cou-
ple could accept termination of the pregnancy on
the basis of 32 repeats. In the context of PD, the
woman, from a presumed non-HD family, was tested
and proved to have 40 CAG repeats. Genetic analysis
of her parents showed that her father has a reduced
penetrance allele of 39 repeats. The woman reported
that her father showed changes in his personality and
cognitive decline since his early sixties which was
explained by alcohol abuse.
Case 3
A man (24 years, carrier HD, 42/23 repeats) and
partner (23 years) wished to not pass on the HD to
future children and applied for prenatal testing in
their first pregnancy. For analysis and interpretation
of results the alleles of both partners were examined.
The results showed 41 repeats in the foetus but, unex-
pectedly, also 39 in the mother. No family history
of HD could be found in the mother’s ancestry, but
analyses showed 39 CAG repeats in mother’s healthy
mother.
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Fig. 1. Four couples at risk for Huntington’s disease applying for prenatal genetic testing. ∗highest number of repeats presented.
Case 4
When she was pregnant, a woman (26 years)
learned that her father was clinically diagnosed with
HD which was confirmed with genetic testing (42
repeats). Her mother had died a few years earlier
from cancer. Six months after delivery she requested
predictive testing because she considered another
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Table 1
Initial and actual risks in 4 couples applying for prenatal testing
for Huntington’s disease
Risk for HD offspring Information on risk should
Information after initial both partners have been
counselling tested
Case 1 Not increased RPA 50%
FPA 50%
Case 2 Very low for FPA 50% (FPA)
Case 3 50% (FPA) 75% (FPA + RPA)
Case 4 25% 100% (FPA + RPA)
pregnancy but only after she was informed about her
genetic status. The test result was 42 and 36 repeats,
implying that her mother must have been carrier of
an RPA but also that her first child has no escape
of being at increased risk. When she became preg-
nant, she applied for prenatal testing and considered
termination only if the foetus would carry the full
penetrance allele. The couple applied for PGD for this
reason but were refused. Because any foetus would
carry at least an RPA, transfer of an affected embryo
was considered unacceptable from a medical ethi-
cal perspective. In this case we see the consequences
of the ignorance of the woman’s parents about their
double risk to transfer an expanded CAG allele.
DISCUSSION
Couples present for genetic counselling and pre-
dictive testing for reasons of planning a family with
the strong wish to exclude passing HD on to the next
generation [27]. Genetic counselling implies that the
couple is comprehensively informed which enables
them to make an informed decision. Comprehen-
sively informed implies that they are informed on
all possible test outcomes of predictive testing (full
expansion, reduced penetrance, intermediate and nor-
mal alleles) and on reproductive options (PD and
PGD) [5]. Couples should also be informed on new
insights from research and clinical experience, with
the inclusion of new insights into the dynamics of
(expanded) repeats. Finally, couples who wish to
exclude HD in future offspring should be acknowl-
edgeable of population risks of HD, which is the core
message of this paper.
According to the international recommenda-
tions concerning reproductive options, preconception
counselling should be available to couples where one
partner is at risk of HD or is a carrier of the HD gene
expansion (rec 7.0.1) [5]. It is also recommended
that the importance of preconception counselling
is stressed, because of the timeframe in making a
decision about testing during an on-going pregnancy.
Moreover, such preparation may help to prevent a
couple at 50% risk first requesting counselling and
testing at the time of a pregnancy, which is a very
stressful situation due to the limited time available
and the potential for consecutive adverse outcomes,
i.e. identification of expanded CAG in the foetus
informing the partner at risk that he/she carries the
expanded repeat (double bad news).
On the basis of the high frequency of intermedi-
ate alleles in the general population and our clinical
experience, all cases of prenatal testing have a pos-
sibility of ascertaining an IA that was inherited from
the non-HD side of the couple, implying that there
are also risks of expanded CAG-repeats for the non-
HD partner [14, 16, 29–31]. Consequently, all couples
considering prenatal testing or PGD for HD may ben-
efit from a discussion on the possibility of unexpected
results that may have uncertain clinical implications
[31]. How couples come to understand and inter-
pret an intermediate allele result need to be further
explored. Individuals may have difficulties to grasp
the clinical implications of intermediate alleles for
themselves and relatives. Especially in families with-
out a generations-long history of HD, understanding
and interpreting intermediate alleles may be a
caveat [32].
These new insights inevitably mean that with the
present policy of testing the non-HD partner in the
context of PD, double bad news should also be reck-
oned with a possible result of such testing. For PGD
the possibility that both partners are carriers entails a
greater chance of the couple being written left with no
embryos that are free of expanded repeats. According
to the international recommendations only embryos
with two non-HD alleles should be transferred (rec
7.2.5). Moreover, as presently the non-HD partner
will only be tested when the HD partner is found to
be at risk, this policy may lead to a false sense of secu-
rity about future offspring. If partner testing depends
on the result for the HD partner, then if the latter is
found to have a normal CAG repeat, prenatal test-
ing or PGD is no longer appropriate. Consequently,
with the present policy an expanded CAG repeat in
the non-HD partner will not be timely identified. Our
cases illustrate these implications of the new data on
population risks.
In case 1, the relief after learning the favourable
result in the man enabled the couple to start a family
free from HD. However, learning that the partner did
have an HD background was devastating. In retro-
spect testing the partner would have been justified to
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exclude any risk to pass the expanded allele on to their
future children. The children have to face now their
50% risk to have inherited the RPA, knowing that the
expansion risk for RPAs is considerable [12]. Test-
ing a partner and finding an expanded allele implies
that he/she might inform the extended family with all
ramifications. Being a messenger of bad news is an
additional strain. However, knowing (for offspring)
outweighs the not-knowing of family members.
Although PD for an individual with an interme-
diate allele of the HD gene (case 2) is justified (rec
7.1.4), it is not recommended to terminate a preg-
nancy on the basis of an intermediate allele result
(rec 7.1.8) [5). Following the recommendations, the
clinical geneticist discussed the risk of expansion of
a 29 IA. Expansion of a 29 IA into the HD-range has
been reported once [33] but the clinical diagnosis was
debated [22, 33, 34]. The couple regarded the unex-
pected outcome of a 40 FPA in the non-HD partner
as a justification of prenatal testing.
Also, for identified carriers of the expanded FPA,
such as in case 3, pre-conceptional testing of the non-
HD partner might have been an acceptable option in
hindsight. The woman in case 4 learned about her
father’s diagnosis when she was pregnant of her first
child. At that time, she and the unborn child were at
50% and 25% risk respectively.
The couples in cases 2, 3 and 4 have received dou-
ble bad news which had to be dealt with. Moreover,
the unexpected information on the expanded allele in
the non-HD partner (case 2 and 3) or in the non-HD
parent (case 4) might lead to reconsideration of the
reproductive decisions the couple had initially made.
All couples felt responsible toward their future off-
spring and made use of prenatal testing or would have
used it (case 1). The risk on an RPA or FPA in the
unborn proved in all cases higher than was previously
thought: 50% in case 1 and 2, 75% in case 3, and 100%
in case 4.
Had the couples been informed on the additional
risks, they might all have decided differently. In our
view, this illustrates the importance of making cou-
ples who wish to avoid transmitting HD to their
offspring aware of those additional risks and to do so
as part of preconception counselling, to allow them
to not only opt for testing the non-HD partner pre-
conceptionally, but also for doing so irrespective of
the testing result of the HD partner.
Some may argue that offering such testing to the
non-HD partner amounts to a form of population
screening in unsuspected individuals without a pos-
itive family history. Moreover, given that HD is a
serious non-treatable late onset disorder, the testing
offer would be at odds with internationally accepted
criteria for responsible population screening [35].
Although we agree that population screening for
expanded CAG repeats would be problematic in view
of the high likelihood of an unfavourable harm to
benefits ratio for those tested, we do not think that
the testing offer under consideration would indeed
fall under the heading of population screening. The
point is that in the context of counselling couples at
risk of passing on HD to their offspring, the addi-
tional information that testing the non-HD partner
may yield is directly relevant for dealing with the
couple’s request for medical help. This not only holds
for the present policy where partner testing is already
done with an eye to the reliability of PD or PGD, but
also for preconception testing of the non-HD part-
ner independently of the results of the HD partner.
Given that the counselees present as a couple with a
shared wish to exclude the HD partner’s transmission
risk, it seems reasonable to assume that they would
also want to be informed about a hitherto unknown
additional risk for that same outcome in the non-HD
partner, as that - as we have shown — may affect the
choices open to them.
No doubt questions arise regarding the benefits
and drawbacks of providing couples with the option
of testing both partners preconceptionally. In addi-
tion to allowing for reproductive decision making on
the basis of more comprehensive information while
avoiding double bad news during pregnancy, the ben-
efits of such a test include reassurance of the absence
of an expanded allele in the non-at risk partner in a
family already burdened by HD. The possible adverse
consequences of the test include anxiety raised by
unfavourable outcomes and the need to inform rel-
atives as detection of an expanded allele may have
far-reaching consequences for personal health and
reproductive choices. Moreover, the offer of testing
the non-HD partner may be felt to add to the bur-
dens of an already emotionally charged situation.
Couples have often spent years of extensive coun-
selling not only to explore reproductive options, but
also to anticipate emotional responses, and face the
impact on their relationship. Adding new far-reaching
information as a result of testing the non-HD partner
may potentially change the dynamics of dealing with
the relevant risks as a couple in ways that are dif-
ficult to predict. This is a further reason for making
sure that such testing is done preconceptionally rather
than under time pressure in the context of a PD or
PGD procedure, but also for carefully evaluating the
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psychosocial impact of the change of policy that this
would entail. On those conditions, however, we feel
that couples wanting to avoid the passing on of HD
to their offspring should indeed be made aware of the
population risk and be offered the option of testing
the non-HD partner accordingly. Consequently, we
suggest adjustments of the recommendations for pre-
dictive testing for HD, as well as for prenatal testing
and PGD [5].
Another question that arises is whether offer-
ing preconception testing of the non-at-risk partner
should also be considered for couples at risk of trans-
mitting other dominant genetic disorders with or
without treatment options. Here again, we have the
opinion that this may well be justified in the light of
the often strongly held wish of these couples to avoid
passing on the condition to their offspring. How-
ever, this needs further exploration that is beyond the
scope of this paper. In each case, and regardless of
the precise condition, the bottom line remains that
the ultimate decision is taken after extensive genetic
counselling in which all pros and cons are considered.
Conclusion
We conclude that couples at risk for HD who
apply for predictive testing because of reproduc-
tive decision-making should be informed about the
population risk of having an expanded CAG repeat.
In addition, partners of individuals at risk for HD
should get access to testing CAG-repeats, preferably
before a planned pregnancy or PGD procedure and
irrespective of test result of the HD partner. Recom-
mendations for predictive genetic testing for HD need
to be adjusted accordingly. We also recommend that
the proposed policy should be carefully evaluated.
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